Subtopic Deep Dive

Immune Tolerance Dendritic Cells
Research Guide

What is Immune Tolerance Dendritic Cells?

Immune Tolerance Dendritic Cells are tolerogenic dendritic cells that induce regulatory T cells through PD-L1, IDO, and cytokine signals like IL-10 to promote immune tolerance and prevent autoimmunity or transplant rejection.

Tolerogenic DCs maintain immature or semi-mature states responsive to environmental cues for tolerance induction (Banchereau and Steinman, 1998; 14,241 citations). They express PD-L1 to engage PD-1 on T cells and secrete IL-10 to suppress effector responses (Hartkopf et al., 2016; 30,894 citations; Moore et al., 2001; 6,619 citations). Over 10 key papers from 1994-2018 detail DC maturation control and tolerance mechanisms.

Curated Papers

Key Challenges

Why It Matters

Tolerogenic DCs enable therapies for autoimmune diseases by expanding regulatory T cells and inhibiting autoreactive responses, as shown in DC immunobiology studies (Banchereau et al., 2000; 6,583 citations). In transplantation, they reduce rejection via IL-10 signaling and PD-L1 pathways (Moore et al., 2001). Sipuleucel-T, a DC-based vaccine, extended survival in prostate cancer, highlighting engineered tolerogenic DCs for immunotherapy (Kantoff et al., 2010; 5,404 citations).

Key Research Challenges

Balancing Tolerance vs Immunity

Tolerogenic DCs must induce tolerance without impairing protective immunity, complicated by maturation signals like TNF-alpha that downregulate antigen presentation (Sallusto and Lanzavecchia, 1994; 5,116 citations). Environmental cues inconsistently promote semi-mature states needed for regulatory T cell generation. Banchereau and Steinman (1998) note DC plasticity as a core hurdle.

Stable Tolerogenic Phenotype

Generating stable immature DCs requires GM-CSF and IL-4, but Toll-like receptor signals like bacterial DNA recognition trigger immunogenic maturation (Hemmi et al., 2000; 6,361 citations). PD-L1 expression varies with cytokine milieu, risking tolerance failure. Hartkopf et al. (2016) highlight checkpoint inconsistencies in clinical translation.

Translating to Human Therapy

Ex vivo DC manipulation for tolerance faces scalability issues, with IL-10 effects differing across species and disease contexts (Moore et al., 2001). Tumor microenvironments polarize DCs away from tolerance, as in TIME studies (Binnewies et al., 2018; 5,583 citations). Clinical trials like Sipuleucel-T show variable efficacy (Kantoff et al., 2010).

Essential Papers

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Andreas D. Hartkopf, Florin‐Andrei Taran, Markus Wallwiener et al. · 2016 · Breast Care · 30.9K citations

Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, P...

Dendritic cells and the control of immunity

Jacques Banchereau, Ralph M. Steinman · 1998 · Nature · 14.2K citations

Interleukin-10 and the Interleukin-10 Receptor

Kevin W. Moore, René de Waal Malefyt, Robert L. Coffman et al. · 2001 · Annual Review of Immunology · 6.6K citations

Interleukin-10 (IL-10), first recognized for its ability to inhibit activation and effector function of T cells, monocytes, and macrophages, is a multifunctional cytokine with diverse effects on mo...

Immunobiology of Dendritic Cells

Jacques Banchereau, Francine Brière, Christophe Caux et al. · 2000 · Annual Review of Immunology · 6.6K citations

Dendritic cells (DCs) are antigen-presenting cells with a unique ability to induce primary immune responses. DCs capture and transfer information from the outside world to the cells of the adaptive...

A Toll-like receptor recognizes bacterial DNA

Hiroaki Hemmi, Osamu Takeuchi, Taro Kawai et al. · 2000 · Nature · 6.4K citations

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

Federica Sallusto, Danielle Lenig, Reinhold Förster et al. · 1999 · Nature · 5.7K citations

Understanding the tumor immune microenvironment (TIME) for effective therapy

Mikhail Binnewies, Edward W. Roberts, Kelly Kersten et al. · 2018 · Nature Medicine · 5.6K citations

Reading Guide

Foundational Papers

Start with Banchereau and Steinman (1998; 14,241 citations) for DC immunity control basics; Sallusto and Lanzavecchia (1994; 5,116 citations) for culture methods; Moore et al. (2001; 6,619 citations) for IL-10 tolerance role.

Recent Advances

Hartkopf et al. (2016; 30,894 citations) on PD-L1 checkpoints; Binnewies et al. (2018; 5,583 citations) on tumor microenvironment effects; Kantoff et al. (2010; 5,404 citations) on clinical DC therapy.

Core Methods

GM-CSF/IL-4 for immature DCs (Sallusto 1994); PD-L1 blockade analysis (Hartkopf 2016); IL-10 signaling assays (Moore 2001); TLR inhibition for tolerance (Hemmi 2000).

How PapersFlow Helps You Research Immune Tolerance Dendritic Cells

Discover & Search

PapersFlow's Research Agent uses searchPapers and citationGraph to map foundational works like Banchereau and Steinman (1998; 14,241 citations), revealing PD-L1 and IL-10 clusters; exaSearch uncovers tolerogenic DC protocols from 250M+ OpenAlex papers; findSimilarPapers links Sallusto and Lanzavecchia (1994) to modern tolerance induction studies.

Analyze & Verify

Analysis Agent employs readPaperContent on Hartkopf et al. (2016) to extract PD-L1 signaling details, verifies claims via CoVe against Moore et al. (2001) IL-10 data, and runs PythonAnalysis for citation trend stats or DC maturation pathway simulations with GRADE scoring for evidence strength in tolerance mechanisms.

Synthesize & Write

Synthesis Agent detects gaps in DC tolerance translation from Banchereau et al. (2000), flags contradictions in maturation cues; Writing Agent uses latexEditText and latexSyncCitations to draft reviews citing 10+ papers, latexCompile for publication-ready output, exportMermaid for PD-L1/IL-10 signaling diagrams.

Use Cases

"Analyze citation trends and co-occurrence of PD-L1, IL-10 in tolerogenic DC papers since 1998."

Research Agent → searchPapers + citationGraph → Analysis Agent → runPythonAnalysis (pandas for trends, matplotlib plots) → CSV export of stats showing Banchereau/Steinman hub with 14k+ citations.

"Write a LaTeX review on DC maturation states for immune tolerance therapies."

Synthesis Agent → gap detection on 10 papers → Writing Agent → latexEditText (add sections), latexSyncCitations (Banchereau 1998, Moore 2001), latexCompile → PDF with tolerance pathway figure.

"Find code for simulating tolerogenic DC cytokine networks from recent papers."

Research Agent → paperExtractUrls on Hemmi et al. (2000) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for TLR signaling models linked to tolerance.

Automated Workflows

Deep Research workflow scans 50+ DC papers via searchPapers → citationGraph → structured report on PD-L1/IL-10 evolution (citing Hartkopf 2016). DeepScan applies 7-step CoVe to verify tolerance claims in Banchereau et al. (2000), with GRADE checkpoints. Theorizer generates hypotheses on DC polarization from Steinman (1998) and Mantovani (2002) data.

Try Doxa for Immune Tolerance Dendritic Cells Research

Frequently Asked Questions

What defines Immune Tolerance Dendritic Cells?

Tolerogenic DCs induce regulatory T cells via PD-L1, IDO, and IL-10 to suppress immunity and prevent autoimmunity or rejection (Banchereau and Steinman, 1998).

What are key methods for generating tolerogenic DCs?

Culture with GM-CSF plus IL-4 maintains immature DCs; avoid TNF-alpha for tolerance; IL-10 enhances regulatory effects (Sallusto and Lanzavecchia, 1994; Moore et al., 2001).

What are the most cited papers?

Banchereau and Steinman (1998; 14,241 citations) on DC immunity control; Hartkopf et al. (2016; 30,894 citations) on PD-1/PD-L1; Banchereau et al. (2000; 6,583 citations) on DC immunobiology.

What are open problems in tolerogenic DC research?

Achieving stable semi-mature phenotypes in vivo; translating ex vivo DCs to scalable therapies; balancing tolerance without infection risk (Binnewies et al., 2018; Kantoff et al., 2010).